Hepion Pharmaceuticals financials at a glance

+ Portfolio

The revenue of Hepion Pharmaceuticals is reported as 0 billion Dollars in the fiscal year 2023. The earnings were -10.98 Dollars per share in 2023, which was 21.7 lower than 2021. And about -0.03921 billion Dollars are reported as free cash flow in the financials of Hepion Pharmaceuticals 2023. No dividends were paid to the shareholders of the Hepion Pharmaceuticals stock NasdaqCM:HEPA in the financial year 2023.

$0.00M

Revenue

$-11.44

Earnings Per Share

0.00%

Gross Margin %

$0.00M

Free Cash Flow

Revenue

0.00

Earnings Per Share

-11.44

Gross Margin %

0.00

Free Cash Flow

0.00

Financials

Year	Year	TTM	2022	2021	2020	2019	2017	2016	2015
Rev.	Revenue	N/A	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-12.51	$-11.44	$-9.40	$-42.00	$-,119.00	$-3,580.64	$-8,611.69	$-11,424.01
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0	0	0	0	0	0	0
Sha.	Shares	N/AM	3.81M	3.81M	3.81M	0.45M	0.14M	0.11M	0.05M
OCF	Operating Cash Flow	N/A	$-39.20M	$-31.22M	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M
FCF	Free Cash Flow	N/A	$-39.22M	$-,130,436.22M	$0.00M	$0.00M	$0.00M	$-16.56M	$0.00M
FCFS	Free Cash Flow Per Share	$-9.61	$-9.18	$-0.45	$-1.68	$-3.73	$-,142.32	$0.00	$0.00

Hepion Pharmaceuticals financials at a glance

Financials

Discover